

View: 19.5mtpa capacity expansion to drive growth; maintain Buy

- UTCEM has announced capacity expansion program to expand its India cement capacity by 19.5 mtpa to 130.9 mtpa (FY23) from 111.4 mtpa (FY20). This expansion consists of 6.7 mtpa ongoing expansion and 12.8 mtpa proposed expansion with a capex of Rs10.5 bn and Rs54.8 bn respectively totaling to Rs65.3 bn. UTCEM plans to commission 2.0/ 4.7/ 12.8 mtpa capacity in FY21/ FY22/ FY23. This capex is spread across East and Central and minor in North/ West region. The average cost of these projects is less than \$60/ tn thus strengthening overall ROCE.
- UTCEM is also planning to add 11.4 mtpa clinker capacity, out of which 2.3 mtpa (Dalla) to be commissioned by FY22 and rest 9.1 mtpa in FY23.
- We expect 5.6%/ 9.1%/ 17.1% revenue/ EBITDA/ APAT CAGR over FY20-23E led by -1.5%/ 8.0%/ 7.0% volume growth and 1.3%/ 1.0%/ 1.0% realization growth in FY21E/ FY22E/ FY23E.
- We broadly maintain our estimates for FY21E/ FY22E/ FY23E as we previously factored 5.6 mtpa capacity addition in FY22E vs. 6.7 mtpa now and proposed expansion of 12.8 mtpa to contribute marginally in FY23E volume as it will commence from Q3FY23 (4.1 mtpa) and Q4FY23 (8.7 mtpa).
- UTCEM will continue to witness healthy operating cash flow (average Rs85.9 bn/year) and free cash flow (average Rs59.2 bn/year) leading to further deleveraging (Net D:E of 0.06x in FY23E vs. 0.42x FY20). UTCEM, being the largest player in Indian cement industry is its biggest advantage. We maintain Buy with an upward revised TP of Rs5,834 based on 15x (14% discount to 5-year average) consolidated Sept'22E EV/EBITDA.

CMP	Rs 4,894
Target / Upside	Rs 5,834 / 19%
NIFTY	13,134

Script Details


Equity / FV	Rs 2,886mn / Rs 10
Market Cap	Rs 1,412bn
	USD 19bn
52-week High/Low	Rs 4,997/ 2,910
Avg. Volume (no)	6,38,601
Bloom Code	UTCEM IN

Price Performance	1M	3M	12M
Absolute (%)	8	24	16
Rel to NIFTY (%)	(3)	10	6

Shareholding Pattern

	Mar'20	Jun'20	Sep'20
Promoters	60.0	60.0	59.9
MF/Banks/FIs	14.2	14.6	15.4
FIIIs	16.5	16.1	15.3
Public / Others	9.3	9.3	9.4

UTCEM Relative to SENSEX



FINANCIALS (Rs Mn)

Particulars	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue	4,16,088	4,21,248	4,20,425	4,58,583	4,95,448
Growth(%)	34.3	1.2	(0.2)	9.1	8.0
EBITDA	73,469	92,836	1,03,581	1,11,633	1,20,690
OPM(%)	17.7	22.0	24.6	24.3	24.4
PAT	25,174	37,054	46,936	52,232	59,429
Growth(%)	(2.0)	47.2	26.7	11.3	13.8
EPS(Rs.)	87.2	128.4	162.6	181.0	205.9
Growth(%)	(2.0)	47.2	26.7	11.3	13.8
PER(x)	56.1	38.1	30.1	27.0	23.8
ROANW(%)	8.4	10.2	11.4	11.5	11.8
ROACE(%)	7.5	11.8	9.2	9.8	10.1

VP Research: Shravan Shah

Tel: +91 22 40969749

E-mail: shravans@dolatcapital.com

Associate: Maulik Shah

Tel: +91 22 40969775

E-mail: mauliks@dolatcapital.com

Associate: Parth Bhavsar

Tel: +91 22 40969775

E-mail: bhavars@dolatcapital.com

Exhibit 1: Change in estimates – Broadly maintain estimates

(Rs mn)	FY21E			FY22E			FY23E		
	New	Old	% change	New	Old	% change	New	Old	%change
Net revenues	4,20,425	4,14,391	1.5	4,58,583	4,51,754	1.5	4,95,448	4,82,188	2.7
EBIDTA	1,03,581	1,01,755	1.8	1,11,633	1,09,595	1.9	1,20,690	1,16,740	3.4
EBIDTA margin (%)	24.6	24.6	8	24.3	24.3	8	24.4	24.2	15
Adj. Net Profit	46,936	45,700	2.7	52,232	50,805	2.8	59,429	57,186	3.9
EPS (Rs)	162.6	158.3	2.7	181.0	176.0	2.8	205.9	198.1	3.9

Source: DART, Company

Exhibit 2: Valuation

Particulars	Rs mn
Assumed EV/EBITDA multiple (x)	15
EBITDA (Sep'22E)	1,16,162
EV	17,42,426
Less: Net Debt (Sep'22E)	58,562
Mcap	16,83,864
Shares o/s (mn)	289
Target Price	5,834
CMP (Rs)	4,894
Upside (%)	19.2

Source: Company, DART

Key takeaways of the Call

Capacity Expansion

- Ultratech to expand total India cement capacity by 19.5 mtpa from 111.4 mtpa in FY20 to 130.9 mtpa in FY23 for a total capex of Rs65.3 bn. Project cost is less than \$60/ tn. UAE capacity will be 5.4 mtpa (current 3.4 mtpa) totalling overall capacity to 136.3 mtpa. Company to also add 11.4 mtpa clinker capacity.
- 19.5 mtpa expansion includes 6.7 mtpa ongoing expansion (Capex of Rs10.5 bn) and 12.8 mtpa (Capex of Rs54.8 bn) proposed expansion. Company plans to add 2.0/ 4.7/ 12.8 mtpa in FY21/ FY22/ FY23.
- More than 70% of capacity is brownfield and balance is greenfield. Pali unit (1.9 mtpa), Cuttack unit (2.2 mtpa) and Dhule unit (1.8 mtpa) will be greenfield expansion.
- With these expansion Ultratech's capacity in East/ Central/ West/ North will increase to 26.2/ 31.0/ 27.7/ 25.7 mtpa. South will remain same at 20.5 mtpa.
- 85% of the output to be blended and they are fully secured with limestone.
- Capex guidance of Rs25 bn each year between FY21-23 including maintenance capex.
- Total capex of Rs65.3 bn doesn't factor land cost except for 3 greenfield plants.
- Net Debt/ EBITDA target of below 1x by FY21 from 1.11 (Sep'20). Company aims to be net debt free by FY23.

- Company plans to touch 160 mtpa capacity by FY30 where it is prepared with land and limestone. They won't stop expanding after this as they believe India is highest growth market.
- Capacity share should be approx. 23-23.5%/ 30% in FY23/ FY30 from currently 22.3%. Market share will be higher.
- These projects have a IRR of 15% and it would be higher if greenfield projects are taken out.

Demand

- Company is very bullish on Central and East market and North market is flourishing.
- Cement per capita consumption increased from 190kg to 229kg in FY20 but in the east it is still at 200kg, which is expected to increase.
- Guided for 8% volume CAGR growth in next 10 years. Company can give positive volume growth in FY21.
- Payments are being paid on time to contractors. Urban housing improving except the luxurious housing. Infra projects are going through the roof. Urban markets improving and Tier 2 also reviving.

Other Updates

- WHRS capacity to be added of 57MW over and above 245 MW renewable energy. 40% of power requirement will be through WHRS for the new expansion.
- Capacity share not a target but only profitable growth.
- Chhattisgarh faces issues of pricing pressure and not in Odisha and Bihar, where the company operates.
- Ultratech's building segment share will be a small part of EBITDA since grey covers a lot.
- Entry barriers in cement business would be readiness and to invest regularly in land and limestone mine.
- Ultratech to expand in White & Putty business shortly. Other segments like RMC and Building products are high margin segments.
- Company has 102 RMC plants and expects to add 20 additional plants by FY21E.
- Company has 2300 UBS stores and plans to double in 3-4 yrs.


Ongoing Expansion

Zone	State	Cement Capacity (mtpa)
Cuttack	Odisha	2.2
Bara & Dalla	UP	3.3
Dankuni	WB	0.6
Patliputra	Bihar	0.6
Total		6.7

Proposed Expansion


Cluster	State	Cement Capacity (mtpa)	Grinding Capacity (mtpa)	Clinker Capacity (mtpa)	Expected commission
Hirmi	Chhattisgarh	4.5	Cuttack - 2.2 Durgapur - 0.6 Sonar Bangla - 0.6 Jharsuguda - 0.6 Hirmi - 0.6	2.7	Q4FY23
Dhar	MP	4.2	Dhar - 1.8 Dhule - 1.8 Neem ka Thana - 0.6	2.7	Q4FY23
Pali	Rajasthan	1.9	Pali	2.7	Q3FY23
Patliputra	Bihar	2.2	Patliputra	1.0	Q3FY23
Total		12.8			

Exhibit 3: Volume (mt)




Source: Company, DART

Exhibit 4: Cost/tn (Rs)




Source: Company, DART

Exhibit 5: Realization/tn (Rs)




Source: Company, DART

Exhibit 6: EBITDA/tn (Rs)




Source: Company, DART

Exhibit 7: Power & fuel cost/tn (Rs)



Source: Company, DART

Exhibit 8: Freight cost/tn (Rs)



Source: Company, DART

Profit and Loss Account

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Revenue	4,21,248	4,20,425	4,58,583	4,95,448
Total Expense	3,28,413	3,16,845	3,46,949	3,74,758
COGS	2,45,064	2,38,731	2,61,941	2,83,369
Employees Cost	25,094	23,589	25,240	26,880
Other expenses	58,255	54,525	59,768	64,509
EBIDTA	92,836	1,03,581	1,11,633	1,20,690
Depreciation	27,022	28,038	29,250	30,927
EBIT	65,814	75,543	82,383	89,763
Interest	19,857	15,294	15,591	13,080
Other Income	6,478	7,449	7,822	8,213
Exc. / E.O. items	0	(4,931)	0	0
EBT	52,423	62,770	74,616	84,898
Tax	(5,682)	20,275	22,385	25,469
RPAT	58,148	42,495	52,232	59,429
Minority Interest	(44)	0	0	0
Profit/Loss share of associates	0	0	0	0
APAT	37,054	46,936	52,232	59,429

Balance Sheet

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Sources of Funds				
Equity Capital	2,886	2,886	2,886	2,886
Minority Interest	75	75	75	75
Reserves & Surplus	3,88,269	4,27,011	4,74,914	5,30,013
Net Worth	3,91,155	4,29,898	4,77,800	5,32,899
Total Debt	2,28,979	2,07,979	1,76,979	1,45,979
Net Deferred Tax Liability	49,120	49,120	49,120	49,120
Total Capital Employed	6,69,329	6,87,072	7,03,974	7,28,074

Applications of Funds

Net Block	5,07,299	4,96,261	4,87,011	4,96,084
CWIP	71,721	79,721	84,721	74,721
Investments	16,850	16,850	16,850	16,850
Current Assets, Loans & Advances	1,97,502	2,10,258	2,33,023	2,65,962
Inventories	41,483	41,467	43,974	47,509
Receivables	22,383	25,341	26,384	28,505
Cash and Bank Balances	5,392	18,628	32,317	55,818
Loans and Advances	14,294	13,344	12,394	11,444
Other Current Assets	71,513	71,479	75,954	80,686

Less: Current Liabilities & Provisions	1,24,042	1,16,018	1,17,631	1,25,544
Payables	35,014	31,100	30,153	32,577
Other Current Liabilities	89,028	84,918	87,477	92,966

sub total

Net Current Assets	73,459	94,240	1,15,392	1,40,419
Total Assets	6,69,329	6,87,072	7,03,974	7,28,074

E – Estimates

Important Ratios

Particulars	FY20A	FY21E	FY22E	FY23E
(A) Margins (%)				
Gross Profit Margin	41.8	43.2	42.9	42.8
EBIDTA Margin	22.0	24.6	24.3	24.4
EBIT Margin	15.6	18.0	18.0	18.1
Tax rate	(10.8)	32.3	30.0	30.0
Net Profit Margin	8.8	11.2	11.4	12.0
(B) As Percentage of Net Sales (%)				
COGS	58.2	56.8	57.1	57.2
Employee	6.0	5.6	5.5	5.4
Other	13.8	13.0	13.0	13.0
(C) Measure of Financial Status				
Gross Debt / Equity	0.6	0.5	0.4	0.3
Interest Coverage	3.3	4.9	5.3	6.9
Inventory days	36	36	35	35
Debtors days	19	22	21	21
Average Cost of Debt	8.2	7.0	8.1	8.1
Payable days	30	27	24	24
Working Capital days	64	82	92	103
FA T/O	0.8	0.8	0.9	1.0
(D) Measures of Investment				
AEPS (Rs)	128.4	162.6	181.0	205.9
CEPS (Rs)	222.0	259.8	282.3	313.1
DPS (Rs)	13.2	13.0	15.0	15.0
Dividend Payout (%)	10.3	8.0	8.3	7.3
BVPS (Rs)	1355.2	1489.5	1655.4	1846.3
RoANW (%)	10.2	11.4	11.5	11.8
RoACE (%)	11.8	9.2	9.8	10.1
RoAIC (%)	10.0	11.3	12.3	13.4
(E) Valuation Ratios				
CMP (Rs)	4894	4894	4894	4894
P/E	38.1	30.1	27.0	23.8
Mcap (Rs Mn)	14,12,387	14,12,387	14,12,387	14,12,387
MCap/ Sales	3.4	3.4	3.1	2.9
EV	15,93,537	15,61,739	15,15,049	14,60,548
EV/Sales	3.8	3.7	3.3	2.9
EV/EBITDA	17.2	15.1	13.6	12.1
P/BV	3.6	3.3	3.0	2.7
Dividend Yield (%)	0.3	0.3	0.3	0.3
(F) Growth Rate (%)				
Revenue	1.2	(0.2)	9.1	8.0
EBITDA	26.4	11.6	7.8	8.1
EBIT	34.4	14.8	9.1	9.0
PBT	51.1	19.7	18.9	13.8
APAT	47.2	26.7	11.3	13.8
EPS	47.2	26.7	11.3	13.8

Cash Flow

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
CFO	89,020	72,120	87,699	97,804
CFI	(41,151)	(18,838)	(23,089)	(25,894)
CFF	(49,911)	(40,046)	(50,920)	(48,409)
FCFF	71,958	47,120	62,699	67,804
Opening Cash	7,397	5,392	18,628	32,317
Closing Cash	5,392	18,628	32,317	55,818


E – Estimates

DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
May-20	Accumulate	4,069	3,529
Jul-20	Accumulate	4,069	3,863
Oct-20	Buy	5,736	4,629

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
--------------------	--------------------------	--------------------------------	------------------------

Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
--------------------------	-------------------------	------------------------------	------------------------

CONTACT DETAILS

Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772
Jubbin Shah	VP - Derivatives Sales	jubbins@dolatcapital.com	+9122 4096 9779
Ashwani Kandoi	AVP - Equity Sales	ashwanik@dolatcapital.com	+9122 4096 9725
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Dinesh Mehta	Co- Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705

Dolat Capital Market Private Limited.

Sunshine Tower, 28th Floor, Senapati Bapat Marg, Dadar (West), Mumbai 400013

Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered broker-dealer Ltd Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer/Entity as informed by Dolat Capital Market Private Limited. from time to time.



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INB010710052 & INF010710052, NSE - INB230710031& INF230710031, Research: INH000000685

Registered office: Office No. 141, Centre Point, Somnath, Daman – 396 210, Daman & Diu

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com
